背景: 免疫疗法组合可能是克服对现有疗法的耐药性的有希望的策略。AFM24是一类第一个双特异性四价先天性细胞增殖剂,结合先天性效应细胞(NK细胞和...查看全文
Affimed(AFMD)06-07 05:15
$Affimed(AFMD)$ 6-K/A [Amend] Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001193125-24-156194 Act: 34 Size: 77 KB 网页链接查看全文
Affimed(AFMD)05-28 18:55
$Affimed(AFMD)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001193125-24-147572 Act: 34 Size: 179 KB 网页链接查看全文
Affimed(AFMD)06-12 20:05
$Affimed(AFMD)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001193125-24-159605 Act: 34 Size: 429 KB 网页链接查看全文
Affimed(AFMD)06-27 04:55
$Affimed(AFMD)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001193125-24-169160 Act: 34 Size: 38 KB 网页链接查看全文
Affimed(AFMD)06-03 18:15
$Affimed(AFMD)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001193125-24-152290 Act: 34 Size: 41 KB 网页链接查看全文
Affimed(AFMD)05-24 05:25
$Affimed(AFMD)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001193125-24-146116 Act: 34 Size: 37 KB 网页链接查看全文
ERLL2014-09-16 04:05
今天盘尾101.5接回来$苹果(AAPL)$ ,买入 $纳斯达克指数ETF-ProShares三倍做多(TQQQ)$ 1018 88.00 Call @2.75。可能是稍微早了点,纳指还可能下跌1%左右$Affimed Therapeutics B.V.(AFMD)$ 还剩一半继续持有。 雅虎call bid太低了,没有成交。算啦。查看全文
ERLL2014-09-16 01:55
$Affimed Therapeutics B.V.(AFMD)$ Affimed是一家临床阶段的生物制药公司,专注于发现和培养具有高度针对性的癌症免疫疗法。其正在开发中的产品属于免疫肿瘤学领域,这是一种治疗癌症的的创新的方法,是利用人体自身的免疫防御系统,以对抗肿瘤细胞的领域。人体防御最有力的细胞类型的白血细胞称...查看全文
$Affimed(AFMD)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001193125-24-169160 Act: 34 Size: 38 KB 网页链接
$Affimed(AFMD)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001193125-24-159605 Act: 34 Size: 429 KB 网页链接
$Affimed(AFMD)$ 6-K/A [Amend] Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001193125-24-156194 Act: 34 Size: 77 KB 网页链接
$Affimed(AFMD)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001193125-24-152290 Act: 34 Size: 41 KB 网页链接
$Affimed(AFMD)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001193125-24-147572 Act: 34 Size: 179 KB 网页链接
$Affimed(AFMD)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001193125-24-146116 Act: 34 Size: 37 KB 网页链接
$Affimed(AFMD)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001193125-24-080581 Act: 34 Size: 168 KB 网页链接
$Affimed(AFMD)$ 20-F Annual and transition report of foreign private issuers [Sections 13 or 15(d)] Accession Number: 0001104659-24-040310 Act: 34 Size: 12 MB 网页链接
$Affimed(AFMD)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001193125-24-064790 Act: 34 Size: 11 KB 网页链接
$Affimed(AFMD)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001193125-24-059965 Act: 34 Size: 29 KB 网页链接